198 related articles for article (PubMed ID: 36792081)
1. [Research Progress of DNA Methylation in Cisplatin Resistance in Lung Cancer].
Sun J; Chen J
Zhongguo Fei Ai Za Zhi; 2023 Jan; 26(1):52-58. PubMed ID: 36792081
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-based DNA methylation editing of NNT rescues the cisplatin resistance of lung cancer cells by reducing autophagy.
Xu C; Jiang S; Ma X; Jiang Z; Pan Y; Li X; Zhang L; Zhou H; Chen S; Xing X; Chen L; Fu W; Wang Q; Chen W; Li D
Arch Toxicol; 2023 Feb; 97(2):441-456. PubMed ID: 36336710
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
Li A; Song J; Lai Q; Liu B; Wang H; Xu Y; Feng X; Sun X; Du Z
Int J Exp Pathol; 2016 Dec; 97(6):412-421. PubMed ID: 27995666
[TBL] [Abstract][Full Text] [Related]
4. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
5. miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2.
Yin Y; Liu H; Xu J; Shi D; Zhai L; Liu B; Wang L; Liu G; Qin J
Oncol Rep; 2018 Dec; 40(6):3479-3488. PubMed ID: 30542710
[TBL] [Abstract][Full Text] [Related]
6. LRPPRC contributes to the cisplatin resistance of lung cancer cells by regulating
Hu Y; Cui J; Jin L; Su Y; Zhang X
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649818
[TBL] [Abstract][Full Text] [Related]
7. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
9. MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data.
Lu M; Hu C; Wu F; Shu L; Pan Y; Liu X; Liu P; Ma F; Deng C; Huang M
Lung Cancer; 2020 Sep; 147():193-197. PubMed ID: 32731058
[TBL] [Abstract][Full Text] [Related]
10. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Chen Y; Zhou H; Yang S; Su D
Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J
Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110
[TBL] [Abstract][Full Text] [Related]
12. KIAA0101 promotes cisplatin resistance through regulating cell apoptosis in lung cancer cells.
Zhang C; Liu Y; Zhao J; Xu J; Pei B; Liu X; Yue X
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):172-176. PubMed ID: 38279448
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin.
Konoshenko M; Lansukhay Y; Krasilnikov S; Laktionov P
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886942
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
Wang W; Dong ML; Zhang W; Liu T
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373
[TBL] [Abstract][Full Text] [Related]
15. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
Xiao Y; Lin FT; Lin WC
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33408251
[TBL] [Abstract][Full Text] [Related]
16. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
[TBL] [Abstract][Full Text] [Related]
17. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.
Li N; Li X; Li S; Zhou S; Zhou Q
Biochem Biophys Res Commun; 2013 Sep; 439(2):187-90. PubMed ID: 23994634
[TBL] [Abstract][Full Text] [Related]
19. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
20. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Tian FM; Zhong CY; Wang XN; Meng Y
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
